Evaluation of a virtual Ayurvedic whole-systems lifestyle intervention for quality of life in breast cancer survivors: An exploratory randomized controlled trial.

Explore (NY)Jun 10, 2026 (epub)
Clinical ResearchOncology (Medical)

Shraddha Ravani, Charles Elder, Sabita Sawhney et al.

✦ AI-curated · Sources linked

In 30 seconds

This exploratory randomized controlled trial evaluated a 12-week virtual Ayurvedic Daily Routine Protocol (ADRP) for breast cancer survivors. The study involved 15 participants who had completed treatment at least three months prior. Results indicated trends toward improved psychological quality of life, sleep disturbance, and gastrointestinal symptoms in the intervention group compared to controls, suggesting the ADRP's potential benefits.

Key findings

  • 100% consent rate and 93% retention at 12 weeks indicate high feasibility.
  • The intervention group showed greater improvement in psychological well-being and gastrointestinal outcomes.
  • Measures of digestive strength indicated a shift toward more balanced digestion over 12 weeks.

Why it matters

Breast cancer survivors often face ongoing treatment-related symptoms that impact their quality of life. This study suggests that personalized lifestyle interventions may offer a supportive approach to enhance well-being and manage symptoms during survivorship.

Source

Published in Explore (NY). This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.